Lactic dehydrogenase estimation in haematological malignancies

Flanagan, N. G.; Ridway, J C; Platt, Caroline; Rowlands, Alison; Whitson, Ann

doi:10.1111/j.1365-2257.1989.tb00170.x

Cited by 9 publications

(5 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With raising LDH levels, more patients presented with extraosseous soft tissue disease, renal failure, high B2MG levels, hypercalcemia, and a shorter survival time with drug resistance. 18,19 On the other hand, we could not find a significant correlation between EM and other patients laboratory parameters like Hb, serum creatinine, serum albumin and β2Mand serum calcium as well. In our study in spite of having a high incidence of EM (6.7%) among patients with serum creatinine ≥ 2, but it was not significant (p > 0.999) while Rafael Rios et al in his study shows that renal failure was significant predictor in patients with early mortality in multiple myeloma.…”

Section: Discussioncontrasting

confidence: 70%

Early Mortality Risk in Patients with Multiple Myeloma

Hussein¹

2020

MJBU

View full text Add to dashboard Cite

Background: advances in treatment has improved greatly survival of multiple myeloma in the last two decades, and this improvement has been endorsed by wider use of novel drugs and tandem autologous stem cell transplantation. however, still there were cases died earlier post diagnosis Objectives: to study the risk factors of early mortality in patients with multiple myeloma in Kurdistan region of Iraq Patients and methods: a 176 cases that were diagnosed with symptomatic multiple myeloma between (January 2012 -July 2019) in cancer centers in Kurdistan region of Iraq. a total of 152 were continued within the study through their recorded sheet. their data were analysed to determine what are the main risk factors that have an impact on early mortality among our myeloma patients. Results: among the total of 152 studied patients nine of them (5.9%) died early. the highest proportion (32.2%) of the sample aged 60-69 years, more than half (57.2%) of the them were male. the majority of the patients (80.9%) have been diagnosed during 2016-2019. the incidence of early death was 8.7% among patients who didn't take the cytotoxic treatment compared with 1.7% of patients who took that treatment, but the difference was not significant (P = 0.089). the early death rate was significantly high (22.2%) among patients who didn't take the immunomodulatory drugs, versus 2.4% of patients who took the immunomodulatory drugs (P = 0.001). the incidence of early mortality was 9.6% among patients with lactate dehydrogenase of ≥ 250 U/L compared with 0% among patients with LDH of less than 250 (P = 0.013). Conclusion:LDH level is a high prediction in finding early mortality among patients with multiple myeloma, and intake of immunomodulatory drugs is highly preventive in early death occurrence.

show abstract

Section: Discussioncontrasting

confidence: 70%

Early Mortality Risk in Patients with Multiple Myeloma

Hussein¹

2020

MJBU

View full text Add to dashboard Cite

show abstract

“…Lactate dehydrogenase act as glycolytic enzyme increase in malignant cell than in normal cell. Malignant cells have a special kind of metabolism in depend on glycolytic sequence and Krebs cycle to obtain its own fuel of energy, so the cells move to exhausted glucose from five to ten times more than normal cells, to convert it to lactate [12]. Under rapid proliferation and immaturity of tumor cells, LDH is released due to multiple cytokine activity and cell membrane damage [13].…”

Section: Discussionmentioning

confidence: 99%

Lactate Dehydrogenase (LDH) as Prognostic Marker in Acute Leukemia Quantitative Method

Elbossaty¹

2017

J Blood Disord Transfus

View full text Add to dashboard Cite

Lactate dehydrogenase enzyme was found in animal and human and play important role in gluconeogenesis process. It distributed in all organs, but the mainly distributed in liver. To evaluated the level of lactate dehydrogenase (LDH) in acute leukemia and investigated its clinical significance with other hematological and clinical parameters. Serum lactate dehydrogenase (LDH) level was investigated in 50 patients with acute leukemia, 17 patients with acute lymphoblastic leukemia and 33 patients with acute myeloid leukemia, in addition to 20 healthy control cases. The relationship between lactate dehydrogenase level and blood cells were analyzed. LDH level was significant elevated in acute leukemia cases as compared to control group, also LDH level was statistically significant increase in acute lymphoblastic leukemia than in acute myeloid leukemia (p<0.001). There were positively correlation between LDH and white blood cells, bone marrow blasts and uric acid; on the other hand, there were negatively correlation between LDH and red blood cells, and platelets. Lactate dehydrogenases represented as supplementary enzymatic tool can be used as differentiation marker between the different types of leukemia not only but also, follow up the patients during treatment period.

show abstract

“…Elevations of serum LDH have major significance in the prognosis of patients with lymphoma and leukemia, in which LDH levels are thought to reflect tumor burden and proliferative activity [33][34][35][36]. In the cases of myeloma with elevated serum LDH, it is hypothesized that a subpopulation of myeloma cells with high LDH content, which are resistant to chemotherapy, exists earlier in the disease course and that such chemotherapy-resistant cells would account for the early relapse and short survival of these patients [6,7].…”

Section: Discussionmentioning

confidence: 99%